Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 3;45(8):1687–1695. doi: 10.1038/s41366-021-00831-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — A Total population*, B week 52 completers^†; C week 16 responders^‡. ^§Statistically significant difference, NB vs. PL at week 52. *All subjects taking a DPP-4i or GLP-1RA at baseline. ^†Subjects from the total population who remained on study treatment through to week 52. ^‡Subjects from the total population who had a weight loss of ≥5% from baseline at week 16. The number of subjects in the model is lower than at baseline since not all subjects have post-baseline data. Note that the attrition from week 16 to week 26 in the total population includes those patients who did not achieve 2% weight loss at week 16 (discontinued from study medication as per LIGHT study protocol and not included in this analysis). Numbers discontinuing at week 16 in the total population (A): NB + DPP-4i, n = 66; NB + GLP-1RA, n = 53; PL + DPP-4i, n = 155; PL + GLP-1RA, n = 173.